Innovation
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden.…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA,…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
1 April 2019
The WHO Technical Report: Pricing of cancer medicines and its impacts (“the Report”) was published in order to address requests made in a resolution adopted by…
Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
1 March 2019
OHE Research Paper 19/02: The combination of rising drug costs in the US and increasing financial stress for individual patients has triggered intense national concern. One…
Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures
1 February 2019
Gene therapies, which can provide cures for diseases, are a new area of research for ICER. Some are within two to three years of becoming available…
Making Outcome-Based Payment a Reality in the NHS
2 January 2019
This report explores the feasibility of introducing one type of flexible payment mechanism – outcome-based payment (OBP) – for cancer medicines into the NHS in England. OBP could help to accelerate patient access to some new medicines and ensure close monitoring of real-world patient benefit.
Making the Most of Health Data to Deliver Pharmaceutical Innovation: What Are the Legal Barriers?
20 December 2018
OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation.
New Publication: Advanced Therapy Medicinal Products and Health Technology Assessment
12 October 2018
A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores…
As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?
26 September 2018
The Center for Global Development and the Office of Health Economics are working on a new approach to drive the next generation of investment for better…